Status: Recruiting
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
Participants needed: 94
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Ubix Therapeutics, Inc.Updated: Nov 19, 2025Locations: 11
Eligibility criteria
Capable of giving signed informed consent [+6]
Systemic antineoplastic therapy or any experimental therapy within 3 weeks or 5... [+15]